Prognosis and Risk Stratification of Patients With Advanced Heart Failure (from PROBE)

Matteo Cameli1, Maria Concetta Pastore1, Giulia E Mandoli1

  • 1Department of Cardiovascular Diseases, University of Siena, Siena, Italy.

Insights

A new echocardiographic score, the PROBE score, accurately predicts major adverse cardiac events in advanced chronic heart failure (CHF) patients. This tool aids in noninvasive, individualized prognosis and risk stratification for better patient management.

Area of Science:

  • Cardiology
  • Echocardiography
  • Heart Failure Research

Background:

  • Advanced chronic heart failure (CHF) lacks comprehensive prognostic scores utilizing echocardiographic data.
  • Existing scores often do not integrate first- and second-level echocardiographic indices for advanced CHF patients.

Purpose of the Study:

  • To develop and validate a novel prognostic echocardiographic score for patients with advanced CHF.
  • To identify key echocardiographic predictors of major adverse cardiac events (MACE) in this population.

Main Methods:

  • Prospective analysis of 110 advanced CHF patients using standard, 3D, and speckle tracking echocardiography.
  • Identification of MACE predictors via ROC analysis (AUC >0.70).
  • Development of the Prognostic Right heart and Atrial index (PROBE) score and validation using Kaplan-Meier analysis.

Main Results:

  • Key predictors identified: left atrial volume index, right ventricular sphericity index, right ventricular fractional area change, and free-wall right ventricular longitudinal strain.
  • The PROBE score demonstrated high predictive accuracy (AUC = 0.90) for MACE.
  • Patients were stratified into low, intermediate, and high-risk groups with significant differences in event-free survival.

Conclusions:

  • The PROBE score, incorporating echocardiographic parameters, effectively predicts MACE in advanced CHF.
  • This score offers a valuable, noninvasive tool for individualized prognosis and risk stratification in advanced CHF.
  • The PROBE score enhances clinical decision-making for patients with advanced chronic heart failure.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
822
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.2K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
757
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
292
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
862
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
242